KAMADA LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,938 ILa | -2.42% |
|
+0.31% | -12.98% |
| 06/03 | Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024 | |
| 06/03 | Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 573M 153M 57.34B 12.73B | Sales 2025 * | 706M 188M 70.6B 15.67B | Capitalization | 1.11B 297M 111B 24.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 46M 12.27M 4.6B 1.02B | Net income 2025 * | 84M 22.4M 8.4B 1.86B | EV / Sales 2024 * | 1.94 x |
| Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 378 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| 1 day | -2.42% | ||
| 1 week | +0.31% | ||
| Current month | -5.97% | ||
| 1 month | -6.83% | ||
| 3 months | -7.98% | ||
| 6 months | +12.48% | ||
| Current year | -12.98% |
1 week
1 918.00
1 986.00
1 month
1 872.002 123.00
Current year
1 872.002 338.00
1 year
1 639.002 338.00
3 years
1 309.002 338.00
5 years
1 309.004 500.00
10 years
1 160.005 020.00
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 09/13/09 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 31/17/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 24/19/24 |
Leon Recanati
BRD | Director/Board Member | 76 | 01/05/01 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 1,938 | -2.42% | 23,512 |
| 24/24/24 | 1,986 | +2.80% | 23,877 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 04:54 pm IST
More quotes
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.98% | 292M | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| +56.40% | 25.23B | |
| -15.35% | 15.36B | |
| -9.14% | 11.95B | |
| -16.85% | 11.6B | |
| -43.00% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- KMDA Stock
